Primary biliary cholangitis (PBC) – Czech Society of Hepatology guidelines for diagnosis and treatment – update (2022)
Radan Brůha Orcid.org 1, Tomáš Fejfar Orcid.org 2, Soňa Fraňková Orcid.org 3, Libuše Husová Orcid.org 4, Petr Husa5, Petr Hůlek2,6, Jan Šperl Orcid.org 3, Petr Urbánek Orcid.org 7, Tomáš Vaňásek Orcid.org 8, Libor Vítek1,9
+ Affiliation
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Fejfar T, Vaňásek T, Hůlek P et al. Primární biliární cholangitida – doporučený postup České hepatologické společnosti ČLS JEP pro diagnostiku a léčbu. Gastroent Hepatol 2018; 72(2): 109–118. doi: 10.14735/amgh2018109.
2. Hirschfield GM, Mason A, Luketic V et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015; 148(4): 751–761. doi: 10.1053/j.gastro.2014.12.005.
3. Nevens F, Andreone P, Mazzella G et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016; 375(7): 631–643. doi: 10.1056/NEJMoa1509840.
4. Kowdley KV, Luketic V, Chapman R et al. Obeticholic Acid PBC Monotherapy Study Group. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology 2018; 67(5): 1890–1902. doi: 10.1002/hep.29569.
5. Hirschfield GM, Beuers U, Corpechot C et al. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017; 67(1): 145–172. doi: 10.1016/j.jhep.2017.03.022.
6. Lindor KD, Bowlus CL, Boyer J et al. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology 2022; 75(4): 1012–1013. doi: 10.1002/hep.32117.
7. D’Amato D, De Vincentis A, Malinverno F et al. Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Rep 2021; 3(2): 100248. doi: 10.1016/j.jhepr.2021.100248.
8. Trauner M, Nevens F, Shiffman ML et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol 2019; 4(6): 445–453. doi: 10.1016/S2468-1253(19)30094-9.
9. Lindor KD, Bowlus CL, Boyer J et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2019; 69(1): 394–419. doi: 10.1002/hep.30145.
10. Gideon M, Hirschfield GM, Dyson JK et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018; 67(9): 1568–1594. doi: 10.1136/gutjnl-2017-315259.
11. National Institute for Health and Care Excellence. Obeticholic acid for treating primary biliary cholangitis. Technology appraisal guidance [TA443]. [online]. Dostupné z: https: //www.nice.org.uk/guidance/ta443/.
12. Harms MH, Hirschfield GM, Florean A et al. Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis. JHEP Rep 2020; 3(1): 100191. doi: 10.1016/ j.jhepr.2020.100191.